Table 1.

Summary of the published clinical trials and outcome measures for cabozantinib therapy

Study	Description	Patients (n)	Primary end point	OS	Median PFS	ORR
Shojaei et al18	Phase Ib drug–drug interaction study	25	Safety and tolerability	15.0 months	12.9 months	PR 28%
Choueiri et al16	Phase III randomized on C vs E	658	PFS	C 21.4 months E 16.5 months	C 7.4 months E 3.8 months	C: PR 21% E: PR 5%

Abbreviations: OS, overall survival; PFS, progression-free survival; ORR, objective response rate; PR, partial response; C, cabozantinib; E, everolimus.